Olfr95, a gene encoding for a member of the olfactory receptor family 8 subfamily G, is integral to the olfactory system in Mus musculus. As a G-protein-coupled receptor (GPCR), Olfr95 plays a crucial role in the detection and transduction of odorant signals, leading to the perception of smell. Structurally, Olfr95 is characterized by a 7-transmembrane domain, typical of GPCRs, which facilitates its binding to odorant molecules and subsequent activation of intracellular signaling pathways. This receptor's ability to recognize and respond to specific odorants underlies the diversity and specificity of the olfactory system, allowing for the detection of a wide range of scents.
Inhibiting Olfr95's function involves complex interactions at the molecular level. Direct inhibition typically requires interference with the receptor's ligand-binding domain, blocking its interaction with odorant molecules and preventing G-protein activation and signal transduction. However, targeting such a specific receptor for direct inhibition can be challenging due to the need for high specificity and the vast diversity of olfactory receptors. Therefore, indirect inhibition strategies are often more feasible. These include modulating the receptor's surrounding biochemical environment or interacting with downstream signaling pathways. For instance, altering membrane composition or receptor conformation can affect Olfr95's ability to bind odorants or transduce signals. Additionally, targeting signaling pathways that regulate receptor desensitization, internalization, or recycling can modulate the receptor's responsiveness and sensitivity to odorants. The chemicals exemplify potential indirect inhibitors, each influencing Olfr95's function through different mechanisms, such as cytochrome P450 enzyme inhibition, modulation of neurotransmitter receptors, or alteration of G-protein coupling efficiency. Understanding the mechanisms governing Olfr95's function and inhibition is vital for deciphering the complex dynamics of olfactory transduction. The strategies for inhibition, both direct and indirect, highlight the intricate interplay between structural and functional aspects of GPCRs and the broader cellular and molecular context in which they operate. Insights gained from studying inhibitors of Olfr95 not only shed light on the modulation of olfactory receptors but also contribute to the understanding of GPCR-mediated signaling in general. This knowledge is essential for exploring the potential modulation of sensory processes and the broader implications of GPCR research in sensory biology and pharmacology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole, an antifungal agent, inhibits cytochrome P450 enzymes, impacting steroid synthesis. This can affect GPCR function, including olfactory receptors like Olfr95, by altering membrane lipid composition and receptor conformation. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol, a non-selective beta and alpha-1 adrenergic blocker, affects GPCR signaling indirectly. By blocking these receptors, it can alter G-protein coupling in related GPCRs, potentially impacting Olfr95 function. | ||||||
Aripiprazole | 129722-12-9 | sc-207300 sc-207300A sc-207300B | 100 mg 1 g 5 g | $179.00 $212.00 $1037.00 | 3 | |
Aripiprazole, an atypical antipsychotic, acts on various neurotransmitter receptors, including GPCRs. Its broad receptor interaction profile can lead to modulation of GPCR pathways, indirectly affecting Olfr95 activity in olfaction. | ||||||
Imipramine hydrochloride | 113-52-0 | sc-207753 sc-207753B sc-207753A | 100 mg 1 g 5 g | $26.00 $45.00 $103.00 | 5 | |
Imipramine, a tricyclic antidepressant with histamine and serotonin antagonist properties, affects GPCR modulation. This can indirectly impact the signaling of receptors like Olfr95 by altering the GPCR milieu. | ||||||
Bisoprolol | 66722-44-9 | sc-278792 | 25 mg | $208.00 | ||
Bisoprolol, a selective beta-1 adrenergic receptor blocker, affects GPCR signaling indirectly. By blocking beta-1 receptors, it can alter G-protein coupling in related GPCRs, potentially impacting Olfr95 function. | ||||||
Lansoprazole | 103577-45-3 | sc-203101 sc-203101A | 500 mg 1 g | $59.00 $176.00 | 6 | |
Lansoprazole, a proton pump inhibitor, can indirectly modulate GPCR activity. By influencing gastric acid secretion, it impacts the histamine-mediated modulation of GPCRs, potentially affecting Olfr95 signaling. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Labetalol, a mixed alpha/beta adrenergic antagonist, modulates GPCR signaling pathways. Its action on both alpha and beta receptors can indirectly affect the signaling of GPCRs like Olfr95. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, can influence GPCR function indirectly. By modulating calcium influx, it affects GPCR-mediated signaling, potentially impacting receptors like Olfr95. | ||||||